Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Wednesday, 29'th Jul 2020
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
06:39pm, Monday, 27'th Jul 2020
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
11:05am, Wednesday, 22'nd Jul 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eastern Time to discuss its second quarter 2020 financial results and
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
11:00am, Tuesday, 21'st Jul 2020
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to di
IPO Update: Annexon Proposes IPO Terms
02:32pm, Monday, 20'th Jul 2020
Annexon has filed to raise $150 million in an IPO of its common stock. The firm is developing treatments for autoimmune and neurodegenerative diseases.
Akcea Appoints New Senior Vice President, Global Medical Affairs
11:00am, Monday, 20'th Jul 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice presid
Coastal Investment Advisors Inc. Sells 4,550 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
07:02am, Saturday, 18'th Jul 2020
Coastal Investment Advisors Inc. lowered its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 45.3% during the second quarter, according to its most recent disclosure with the Securities
Did Hedge Funds Make The Right Call On Ionis Pharmaceuticals, Inc. (IONS) ?
07:31pm, Friday, 17'th Jul 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
USANA (USNA) to Report Q2 Earnings: What's in the Cards?
12:00am, Friday, 17'th Jul 2020
Stocks Analysis by Zacks Investment Research covering: Ionis Pharmaceuticals Inc, USANA Health Sciences Inc, United Therapeutics Corporation, Theravance Biopharma Inc. Read Zacks Investment Research's
MERIAN GLOBAL INVESTORS UK Ltd Decreases Stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
06:12pm, Thursday, 16'th Jul 2020
MERIAN GLOBAL INVESTORS UK Ltd lessened its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the Secur
Ionis Is A Long On Neurological Medicines Pipeline
07:28pm, Wednesday, 15'th Jul 2020
Ionis is the leader in antisense RNA technology. Neurological medicines are a key part of its pipeline.
uniQure: Moving Forward After The CSL Behring Deal
06:42pm, Tuesday, 14'th Jul 2020
uniQure out-licensed AMT-061 which is currently in an open-label pivotal study in exchange for approximately $2 billion in milestone payments plus royalties.
Ionis Pharmaceuticals (IONS) Presents On Neurology Franchise - Slideshow
02:23pm, Tuesday, 14'th Jul 2020
The following slide deck was published by Ionis Pharmaceuticals, Inc. in conjunction with this event..
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares Bought by DNB Asset Management AS
05:22am, Tuesday, 14'th Jul 2020
DNB Asset Management AS raised its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 12.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
Transthyretin Amyloidosis Markets and Drugs to 2029 - ResearchAndMarkets.com
12:00am, Tuesday, 14'th Jul 2020
The
